A term from Peter Attia's Outlive, cited by Cohen, for a shift in medicine from reactive treatment of disease (wait for symptoms, then intervene) to personalized, preventive management of long-term health risk — using individual data to intervene before disease onset rather than after.
Cohen cites it as a domain he's optimistic AI will accelerate (more personalized data, cheaper continuous monitoring, faster iteration on individual risk models), though it isn't something LinkedIn is building — an example of where he expects the same idea-to-design compression (see Idea-to-Design vs. Code-to-Launch (AI Investment Gap)) to show up outside software.